Knockdown of p21-activated Kinase 6 Inhibits Prostate Cancer Growth and Enhances Chemosensitivity to Docetaxel
Authors:
- Xiaojuan LiXLXiaojuan Li
- Bing LiaoBLBing Liao
- Yong LiuYLYong Liu
- Jieying WuJWJieying Wu
- Xiaoxu YuanXYXiaoxu Yuan
- Bin OuyangBOBin Ouyang
- Qipeng SunQSQipeng Sun
- Xin GaoXGXin Gao
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- p21-activated kinases in cancerNature Reviews Cancer, 2006
- Docetaxel for treatment of solid tumours: a systematic review of clinical dataThe Lancet Oncology, 2005
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Mechanism of p21-activated Kinase 6-mediated Inhibition of Androgen Receptor SignalingJournal of Biological Chemistry, 2004
- Rho GTPases in cell biologyNature, 2002
- Emerging functions of p21‐activated kinases in human cancer cellsJournal of Cellular Physiology, 2002
- p21-Activated kinases: three more join the PakThe International Journal of Biochemistry & Cell Biology, 2002
- AR and ER Interaction with a p21-Activated Kinase (PAK6)Molecular Endocrinology, 2002
- Androgen Receptor Specifically Interacts with a Novel p21-activated Kinase, PAK6Journal of Biological Chemistry, 2001